Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Design of pharmacokinetic studies for latent covariates.
Lagishetty CV, Coulter CV, Duffull SB. Lagishetty CV, et al. J Pharmacokinet Pharmacodyn. 2012 Feb;39(1):87-97. doi: 10.1007/s10928-011-9231-3. Epub 2011 Dec 10. J Pharmacokinet Pharmacodyn. 2012. PMID: 22161222
Current strategies to streamline pharmacotherapy for older adults.
Schlender JF, Vozmediano V, Golden AG, Rodriguez M, Samant TS, Lagishetty CV, Eissing T, Schmidt S. Schlender JF, et al. Among authors: lagishetty cv. Eur J Pharm Sci. 2018 Jan 1;111:432-442. doi: 10.1016/j.ejps.2017.10.015. Epub 2017 Oct 12. Eur J Pharm Sci. 2018. PMID: 29032303 Review.
Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration.
Zimmermann ES, Laureano JV, Dos Santos CN, Schmidt S, Lagishetty CV, de Castro WV, Dalla Costa T. Zimmermann ES, et al. Among authors: lagishetty cv. Antimicrob Agents Chemother. 2015 Nov 30;60(2):946-54. doi: 10.1128/AAC.02317-15. Print 2016 Feb. Antimicrob Agents Chemother. 2015. PMID: 26621623 Free PMC article.
Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two-drug regimen in SWORD-1/-2 phase 3 studies.
Mehta R, Lagishetty CV, Angelis K, Aylott A, Kahl L, Blair L, Matthews J, Wynne B, Crauwels H, Underwood M, Adkison KK. Mehta R, et al. Among authors: lagishetty cv. Br J Clin Pharmacol. 2023 Jul;89(7):2190-2200. doi: 10.1111/bcp.15683. Epub 2023 Mar 1. Br J Clin Pharmacol. 2023. PMID: 36740580 Clinical Trial.
11 results